Cystic Fibrosis | CHOP Research Institute
 

Cystic Fibrosis

Published on
Jun 7, 2024
CHOP receives a collaborative grant to drive cystic fibrosis research forward, Dr. John Maris honored with Pitcher of Hope Award, and more.
Published on
Mar 12, 2024
Understanding how CF newborn screening algorithms contribute to disparities is essential to make screening programs more equitable.
Use of elexacaftor-texacaftor-ivacaftor ("ETI"), also known as Trikafta, is associated with weight gain in most people with cystic fibrosis (CF) who take this medication.
Published on
Dec 8, 2023
Our research news roundup highlights the improvements made in CAR therapies through structural biology discoveries and cost reduction strategies.
Published on
Sep 3, 2021
This week’s In the News highlights two new studies, a new grant, the new director of the Cystic Fibrosis Center, and a physician’s new role.

Dr. Ren's primary research focus is to develop better methods to assess lung disease in infants and young children using advanced pulmonary function testing and imaging.

E-mail:
renc [at] chop.edu

The Children’s Hospital of Philadelphia is seeking healthy adolescents and young adults ages 16-22 years old, to participate in the Muscle Accrual in Cystic Fibrosis Research Study.

The purpose of this research study is to examine and understand the various mechanisms that contribute to Cystic Fibrosis Related Diabetes and gain a better understanding of potential means to treat Cystic Fibrosis Related Diabetes.

The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD.

The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance.